Bosutinib versus Imatinib in the Initial Management of Chronic-Phase Chronic Myeloid Leukemia (CML-CP)


Bosutinib versus Imatinib in the Initial Management of Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
Slides from a presentation at ASH 2010 and transcribed comments from recent interviews with Susan M O’Brien, MD (1/4/11) and Neil P Shah, MD, PhD (1/4/11)

Gambacorti-Passerini C et al. An ongoing phase 3 study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia. Proc ASH 2010;Abstract 208.

Dr O'Brien is Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Dr Shah is Co-Leader of the Hematologic Malignancies Program at the UCSF Helen Diller Comprehensive Cancer Center and Assistant Professor of Medicine at the University of California in San Francisco, California.